Erratum to: nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial.

Tehfe, Mustapha; Dowden, Scot; Kennecke, Hagen; El-Maraghi, Robert; Lesperance, Bernard; Couture, Felix; Letourneau, Richard; Liu, Helen; Romano, Alfredo

Tehfe, Mustapha; Dowden, Scot; Kennecke, Hagen; El-Maraghi, Robert; Lesperance, Bernard; Couture, Felix; Letourneau, Richard; Liu, Helen; Romano, Alfredo.

Afiliação

Tehfe M; Centre hospitalier de l'université de Montréal (CHUM), Montreal, QC, Canada. mustapha.tehfe.chum@ssss.gouv.qc.ca.
Dowden S; Tom Baker Cancer Centre, Calgary, AB, Canada.
Kennecke H; British Columbia Cancer Agency, Vancouver, BC, Canada.
El-Maraghi R; Royal Victoria Regional Health Centre, Barrie, ON, Canada.
Lesperance B; Hôpital du Sacré-Coeur de Montreal, Montreal, QC, Canada.
Couture F; Centre hospitalier universitaire de Québec (CHUQ), Hôtel-Dieu de Quebec, CHUM, Montreal, QC, Canada.
Letourneau R; Centre hospitalier de l'université de Montréal (CHUM), Montreal, QC, Canada.
Liu H; Celgene Corporation, Summit, NJ, USA.
Romano A; Celgene Corporation, Summit, NJ, USA.

Adv Ther ; 34(1): 277-279, 2017 01.

Article em En | MEDLINE | ID: mdl-27885491

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article